Annual screening beneficial in high-risk PCa patients

Annual PSA screening yields a greater quality-adjusted life expectancy among patients who have a high risk of developing metastatic disease in comparison to unscreened patients, according to a recent study.

Related Videos

Related Content

Advertisement

July 18th 2025

Experts urge FDA to remove black box warning on low-dose vaginal estrogen

Hannah Clarke

In a panel meeting convened by the FDA, experts urged the agency to revise or remove the outdated boxed warning on hormone therapies for menopause.

July 15th 2025

Pearls & Perspectives: Testosterone and the Future of Men’s Health, with John P. Mulhall, MD

Amy M. Pearlman, MD

Mulhall offers an unfiltered, evidence-based deep dive into testosterone evaluation and treatment nuances.

July 18th 2025

Urology in focus: Key moments from 2025

Hannah Clarke

Take a look back through some of the top stories from the first half of the year.

June 30th 2025

Pearls & Perspectives: Disruptive Innovation in Urology, with Sijo J. Parekattil, MD

Amy M. Pearlman, MD

Pearlman and Parekattil dig deep into novel surgical and non-surgical approaches to chronic orchialgia and pelvic pain.

July 17th 2025

FDA, French ANSM greenlight pivotal trial of UroActive smart implant for male SUI

Hannah Clarke Jason M. Broderick

The SOPHIA2 trial will assess the safety and efficacy of the UroActive implant in men with SUI.

July 17th 2025

FDA grants priority review to NDA for TAR-200 in BCG-unresponsive NMIBC

Hannah Clarke

The new drug application for TAR-200 is supported by data from cohort 2 of the phase 2b SunRISe-1 trial.

Related Content

Advertisement

July 18th 2025

Experts urge FDA to remove black box warning on low-dose vaginal estrogen

Hannah Clarke

In a panel meeting convened by the FDA, experts urged the agency to revise or remove the outdated boxed warning on hormone therapies for menopause.

July 15th 2025

Pearls & Perspectives: Testosterone and the Future of Men’s Health, with John P. Mulhall, MD

Amy M. Pearlman, MD

Mulhall offers an unfiltered, evidence-based deep dive into testosterone evaluation and treatment nuances.

July 18th 2025

Urology in focus: Key moments from 2025

Hannah Clarke

Take a look back through some of the top stories from the first half of the year.

June 30th 2025

Pearls & Perspectives: Disruptive Innovation in Urology, with Sijo J. Parekattil, MD

Amy M. Pearlman, MD

Pearlman and Parekattil dig deep into novel surgical and non-surgical approaches to chronic orchialgia and pelvic pain.

July 17th 2025

FDA, French ANSM greenlight pivotal trial of UroActive smart implant for male SUI

Hannah Clarke Jason M. Broderick

The SOPHIA2 trial will assess the safety and efficacy of the UroActive implant in men with SUI.

July 17th 2025

FDA grants priority review to NDA for TAR-200 in BCG-unresponsive NMIBC

Hannah Clarke

The new drug application for TAR-200 is supported by data from cohort 2 of the phase 2b SunRISe-1 trial.